Skip to main content
NOVA EYE MEDICAL LIMITED logo

NOVA EYE MEDICAL LIMITED — Investor Relations & Filings

Ticker · EYE ISIN · AU0000094252 ASX Manufacturing
Open in API
Filings indexed 736 across all filing types
Latest filing 2026-05-05 Share Issue/Capital Cha…
Country AU Australia
Listing ASX EYE

About NOVA EYE MEDICAL LIMITED

https://www.nova-eye.com

Nova Eye Medical Limited is a medical technology company focused on the development, manufacture, and commercialization of advanced ophthalmic treatment technologies. The company specializes in solutions for glaucoma and age-related macular degeneration (AMD). Its primary product portfolio includes the iTrack™ portfolio of canaloplasty microcatheters, designed for minimally invasive glaucoma surgery (MIGS) to restore the eye's natural outflow pathway. Additionally, the company offers the Molteno3® glaucoma drainage device for complex glaucoma cases. Nova Eye Medical is also advancing 2RT®, a proprietary nanosecond laser therapy intended to treat early-stage AMD by stimulating a biological healing response in the retina. The company serves a global market of ophthalmic surgeons and specialists, providing clinical-stage and commercialized tools to improve patient outcomes in vision-threatening conditions.

Recent filings

Filing Released Lang Actions
Application for quotation of securities - EYE 7 pages 19.9KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 2A form, which is a standard ASX announcement for the application for quotation of securities. It details the issuance and quotation of securities under an employee incentive scheme, including the number of securities, issue date, and class. It is not a financial report, earnings release, or management discussion, but rather a regulatory announcement related to capital changes. This fits the category of Share Issue/Capital Change (SHA). The document length and content confirm it is the actual announcement, not just a notice of a report publication.
2026-05-05 English
Notification regarding unquoted securities - EYE 6 pages 18.4KB
Share Issue/Capital Change Classification · 100% confidence The document is an Appendix 3G notification, which is a regulatory form used to notify the issue, conversion, or payment up of unquoted equity securities, specifically performance rights under an employee incentive scheme. It details the number of securities issued, issue date, and compliance with ASX listing rules. This is a capital change announcement related to securities issuance rather than a full financial report or other types of filings. The document length is about 4661 characters, and it is a direct notification of a share issue event. Therefore, the appropriate classification is Share Issue/Capital Change (SHA).
2026-05-05 English
Q3FY26 Investor Presentation May26 16 pages 1.0MB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Investor Presentation Quarterly Report May 2026' and contains detailed financial data including quarterly revenue, EBITDA, sales guidance, and operational results. It includes forward-looking statements, market positioning, product information, and detailed financial tables for Q3FY26 and comparisons to prior periods. The document is about 11,649 characters long, which is substantial and contains actual financial data and analysis, not just an announcement or summary. It is clearly a presentation aimed at investors with comprehensive financial and operational information for a quarter, consistent with an Interim / Quarterly Report. Therefore, the document fits best into the category of Interim / Quarterly Report (IR). Q3 2026
2026-05-04 English
EYE lifts Sales Guidance 2 pages 235.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX release dated 5 May 2026 from Nova Eye Medical Limited announcing a new monthly sales record and an upgrade to FY26 sales guidance. It contains sales figures, growth percentages, and updated sales revenue guidance. The document is relatively short (4456 characters) and focuses on sales performance and guidance upgrade rather than detailed financial statements or comprehensive financial analysis. It is not a full annual or interim report, nor is it a regulatory filing or certification. The content fits the description of a Capital/Financing Update as it provides updates on company sales performance and guidance, which relates to the company's financial outlook and capital expectations. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2026-05-04 English
Investor Webinar Tuesday 5 May @ 11.30 AEST 2 pages 188.9KB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated 30 April 2026 inviting shareholders and interested parties to an investor webinar scheduled for 5 May 2026. The webinar will discuss the company's March 2026 quarterly results. The document contains no actual financial data or detailed financial analysis, only an invitation and logistical details for the webinar. It is short (2451 characters) and serves as a notice for an upcoming event rather than a report or transcript. Therefore, it is best classified as an Investor Presentation (IP) announcement, as it relates to a presentation focused on financial results and company updates for investors.
2026-04-29 English
Quarterly Activities/Appendix 4C Cash Flow Report 13 pages 725.4KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities and Cashflow Report – March 2026' and contains detailed financial data for the quarter ended 31 March 2026, including sales performance, EBITDA, cash flow from operations, and guidance updates. It includes actual financial figures, operating results, and cash flow statements, which are characteristic of an interim or quarterly report. The presence of detailed financial tables and analysis confirms it is a substantive financial report for a period shorter than a full fiscal year. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2026
2026-04-28 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.